Gland Pharma Ltd

Net profit of Gland Pharma rose 12.32% to Rs 183.68 crore in the quarter ended September 2025 as against Rs 163.53 crore during the previous quarter ended September 2024. Sales rose 5.77% to Rs 1486.88 crore in the quarter ended September 2025 as against Rs 1405.83 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales1486.881405.83 6 OPM %21.1121.13 - PBDT390.23350.60 11 PBT283.92256.78 11 NP183.68163.53 12 Powered by Capital Market - Live

Gland Pharma will hold a meeting of the Board of Directors of the Company on 3 November 2025.Powered by Capital Market - Live

Gland Pharma Ltd rose for a third straight session today. The stock is quoting at Rs 1915.3, up 1.55% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.43% on the day, quoting at 24628.25. The Sensex is at 80338.6, down 0.47%. Gland Pharma Ltd has dropped around 2.16% in last one month. Meanwhile, Nifty Pharma index of which Gland Pharma Ltd is a constituent, has dropped around 1.55% in last one month and is currently quoting at 21915.4, down 0.26% on the day. The volume in the stock stood at 1.1 lakh shares today, compared to the daily average of 2.57 lakh shares in last one month.The PE of the stock is 27.37 based on TTM earnings ending June 25.Powered by Capital Market - Live

The company also received tentative approval for the (0.2 Units/mL) RTU vials of the same formulation. The product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), VASOSTRICT Injection (0.4 Units/mL) and (0.2 Units/mL) of PH Health. This product is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines. According to IQVIA, the product recorded U.S. sales of approximately USD 45 million for the twelve months ending June 2025. Gland Pharma is one of the largest and fastest-growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India, and other markets. It has a wide range of injectables, including vials, ampoules, pre-filled syringes, lyophilized vials, dry powders, infusions, oncology, and ophthalmic solutions. The company also pioneered Heparin technology in India. The company's consolidated net profit surged 49.88% to Rs 215.48 crore in Q1 FY26 as against Rs 143.76 crore posted in Q1 FY25. Revenue from operations increased by 7.41% YoY to Rs 1,505.62 crore for the quarter ended 30 June 2025. The counter shed 0.05% to Rs 1,941 on the BSE. Powered by Capital Market - Live

Gland Pharma has received approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application filed for Vasopressin in 5% Dextrose Injection, 40 Units per 100 mL (0.4 Units per mL) RTU Vials and tentative approval for Vasopressin in 5% Dextrose Injection, 20 Units per 100 mL (0.2 Units per mL) RTU Vials. The Product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), VASOSTRICT Injection 40 Units per 100 mL (0.4 Units per mL) and 20 Units per 100 mL (0.2 Units per mL) of PH Health Limited (PH Health). This Product is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines. According to IQVIA, the product had US sales of approximately USD 45 million for the twelve months ending June 2025. Powered by Capital Market - Live

Revenue from operations increased by 7.41% YoY to Rs 1,505.62 crore for the quarter ended 30 June 2025. Profit before tax (PBT) stood at Rs 312.74 crore in Q1 FY26, up 43.29% from Rs 218.25 crore recorded in Q1 FY25. EBITDA for the quarter came in at Rs 367.8 crore, marking a 38.58% growth YoY. The EBITDA margin improved to 24%, compared to 19% in the same period last year. On the geographical revenue front, Revenue from the US market stood at Rs 744.3 crore (down 2.42% YoY), revenue from Europe was at Rs 330.2 crore (up 28.68% YoY), Canada, Australia, and New Zealand stood at Rs 73.9 crore (up 65.32% YoY), Revenue from India was at Rs 59.4 crore (up 12.71% YoY) and the rest of the world was at Rs 297.8 crore (up 4.52% YoY) during the period under review. Total capex for the quarter rose 23.39% to Rs 78.6 crore in Q1 FY26, compared to Rs 63.7 crore in the same period last year. The company's total R&D expenses were Rs 46 crore in Q1 FY26, representing 4.4% of revenue. During Q1 FY26, the company launched 12 new molecules in regulated markets, including Colistimethate, Epinephrine, Vancomycin (in three new strengths), Liraglutide, and Acetaminophen Bags. Additionally, one ANDA (Abbreviated New Drug Application) was filed and nine were approved in Q1 FY26, contributing to a cumulative total of 372 ANDA filings in the U.S. (325 approved, 47 pending). Srinivas Sadu, Executive Chairman of Gland Pharma, said, 'We're off to a positive start this year with a growth in revenue and a significant jump in profitability, which was driven by a strong performance in our base business and a turnaround at Cenexi. These results show our strategic priorities are progressing and we are strengthening our capabilities, adding new capacity, and boosting R&D with complex products and key partnerships. We're committed to building on this strong foundation, improving our performance, and reinforcing Gland's path toward sustainable growth' Shyamakant Giri, CEO, Gland Pharma, said, 'This quarter's performance, with improved margins and Cenexi achieving EBITDA break even, reinforces the progress we are making in delivering our long-term vision. By enhancing our base business, investing in differentiated products, and driving operational efficiencies, we are positioning ourselves for sustained growth. At the same time, our continued focus on R&D, adherence to global quality standards, and investment in capability building position us to scale further, tap new markets, and deliver long-term value.' Gland Pharma is one of the largest and fastest-growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India, and other markets. It has a wide range of injectables, including vials, ampoules, pre-filled syringes, lyophilized vials, dry powders, infusions, oncology, and ophthalmic solutions. The company also pioneered Heparin technology in India. Powered by Capital Market - Live

Net profit of Gland Pharma rose 49.89% to Rs 215.48 crore in the quarter ended June 2025 as against Rs 143.76 crore during the previous quarter ended June 2024. Sales rose 7.41% to Rs 1505.62 crore in the quarter ended June 2025 as against Rs 1401.71 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales1505.621401.71 7 OPM %24.4318.86 - PBDT413.79310.21 33 PBT312.74218.25 43 NP215.48143.76 50 Powered by Capital Market - Live

Gland Pharma Ltd is up for a third straight session today. The stock is quoting at Rs 2085.7, up 1.62% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.08% on the day, quoting at 24701.85. The Sensex is at 80911.87, up 0.03%. Gland Pharma Ltd has gained around 13.75% in last one month. Meanwhile, Nifty Pharma index of which Gland Pharma Ltd is a constituent, has gained around 4.35% in last one month and is currently quoting at 22761.15, up 1.04% on the day. The volume in the stock stood at 1.9 lakh shares today, compared to the daily average of 4.88 lakh shares in last one month.The PE of the stock is 31.02 based on TTM earnings ending March 25.Powered by Capital Market - Live

Gland Pharma will hold a meeting of the Board of Directors of the Company on 5 August 2025.Powered by Capital Market - Live

Gland Pharma Ltd rose for a fifth straight session today. The stock is quoting at Rs 1994.3, up 1.19% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is down around 0.07% on the day, quoting at 25193.55. The Sensex is at 82521.43, down 0.14%. Gland Pharma Ltd has added around 14.97% in last one month. Meanwhile, Nifty Pharma index of which Gland Pharma Ltd is a constituent, has added around 5.37% in last one month and is currently quoting at 22593.9, up 0.68% on the day. The volume in the stock stood at 5.06 lakh shares today, compared to the daily average of 3.63 lakh shares in last one month.The PE of the stock is 29.8 based on TTM earnings ending March 25.Powered by Capital Market - Live